Ranbaxy plans to re-launch its former flagship brand Sotret in US

21 May 2012 Evaluate

Ranbaxy Laboratories’ former flagship skincare brand Sotret will soon be re-launched in the US through Cipher Pharmaceuticals, a Canada based company. The final review of the drug will be conducted on May 29, 2012 by the US drug regulator - USFDA.

Sotret along with other 30 drugs were banned in September 2008 by the USFDA for violating US drug manufacturing norms. Prior to the ban, Sotret had generated approximately $50 million in annual sales and was Ranbaxy's third best selling drug globally.

Cipher is the marketing partner for Sotret which specializes in developing improved formulations of existing drugs out-licenses them to partners for a fee.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×